Consistent with the reduction of IL-1α, CCL2, and CCL3 in SHP2-silenced tumors (Figure 6H and Supplemental Figure 7, B and C), IHC revealed that tumor-infiltrating CD45+ hematopoietic cells and F4/80+ macrophages were significantly reduced in SHP2-silenced B16F10 tumors compared with controls (Figure 7, B–E). The gene discussed is PTPRC; the disease is neoplasm.